Yorktown Management & Research Co Inc Invests $559,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Yorktown Management & Research Co Inc purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,600 shares of the biotechnology company’s stock, valued at approximately $559,000.

Several other institutional investors have also added to or reduced their stakes in SRPT. Creative Planning lifted its position in shares of Sarepta Therapeutics by 11.7% during the 2nd quarter. Creative Planning now owns 7,937 shares of the biotechnology company’s stock valued at $1,254,000 after acquiring an additional 829 shares during the period. Truist Financial Corp lifted its position in shares of Sarepta Therapeutics by 86.5% during the 2nd quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock valued at $632,000 after acquiring an additional 1,857 shares during the period. Cetera Investment Advisers lifted its position in shares of Sarepta Therapeutics by 8.5% during the 2nd quarter. Cetera Investment Advisers now owns 13,013 shares of the biotechnology company’s stock valued at $2,056,000 after acquiring an additional 1,022 shares during the period. Handelsbanken Fonder AB lifted its position in shares of Sarepta Therapeutics by 12.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 23,815 shares of the biotechnology company’s stock valued at $2,974,000 after acquiring an additional 2,600 shares during the period. Finally, Connective Portfolio Management LLC acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth $1,624,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Up 0.2 %

Shares of NASDAQ:SRPT opened at $114.08 on Wednesday. The business’s 50 day simple moving average is $122.45 and its two-hundred day simple moving average is $126.50. The firm has a market cap of $10.90 billion, a P/E ratio of 91.26 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. Raymond James reissued an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Piper Sandler lowered their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday, January 30th. Finally, Evercore ISI lowered their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Insiders Place Their Bets

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.